Using AI to predict growth of ovarian cancer organoids
Development and Validation of Growth Prediction Model for Ovarian Cancer Organoids Based on Bright Field Image and Deep Learning
This study is testing if artificial intelligence can help predict how ovarian cancer cells grow in lab-created samples from patients to improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | Female |
| Sponsor | Chongqing University Cancer Hospital Academic / other |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT06317610 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect bright field images of patient-derived organoids from individuals with ovarian cancer. By utilizing artificial intelligence, the study seeks to develop and enhance algorithms that can accurately predict the growth patterns of these organoids. The approach involves analyzing the images to better understand tumor behavior and potentially improve treatment strategies. Participants will provide tumor tissues or malignant effusions for the establishment of organoids, which will be monitored for growth predictions.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a confirmed diagnosis of epithelial ovarian cancer who can provide sufficient tumor samples.
Not a fit: Patients with non-epithelial ovarian cancer or insufficient tumor samples will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate predictions of ovarian cancer progression, aiding in personalized treatment plans.
How similar studies have performed: While the use of AI in cancer research is growing, this specific approach to predicting growth in ovarian cancer organoids is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have histologically confirmed diagnosis of epithelial ovarian cancer * Patients received biopsy or puncture to obtain tumor tissues or malignant effusion * Patients voluntarily participated in the study and signed informed consent. Exclusion Criteria: * Non-epithelial ovarian cancer * No sufficient amount of tumor tissues or malignant effusion for organoids establishment.
Where this trial is running
Chongqing, Chongqing
- Chongqing Cancer Hospital — Chongqing, Chongqing, China (Recruiting)
Study contacts
- Principal investigator: Dongling Zou, M.D. — Chongqing University Cancer Hospital
- Study coordinator: Dongling Zou, MD
- Email: cqzl_zdl@163.com
- Phone: 13657690699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.